Arbutus announces 2024 corporate objectives and provides financial update

Additional data from two on-going phase 2a clinical trials evaluating imdusiran, our rnai therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024

ABUS Ratings Summary

ABUS Quant Ranking